



FemPhyllo™

Compatibility Table

Active Pharmaceutical Ingredient	Range of tested concentration	Beyond-use Date (days)
Benzocaine + Resorcinol	5 mg + 2 mg	180*
Benzocaine + Resorcinol	50 mg + 20 mg	180*
Clindamycin phosphate	10 mg to 50 mg	180*
Clotrimazole	10 mg to 20 mg	180*
Dehydroepiandrosterone	10 mg to 50 mg	180*
Dienogest	1 mg to 5 mg	180*
Econazole nitrate	10 mg to 50 mg	180*
Estradiol	0.25 mg to 2 mg	180*
Estriol	1 mg to 10 mg	180*
Gestrinone	2.5 mg to 5 mg	180
Itraconazole	10 mg to 50 mg	180*
Ketoconazole	10 mg to 50 mg	180*
Metronidazole	10 mg to 50 mg	180*
Miconazole nitrate	10 mg to 50 mg	180
Miodesin®	50 mg to 100 mg	180*
Progesterone	20 mg to 100 mg	180
Tenofovir	10 mg to 50 mg	180*
Terconazole	40 mg to 80 mg	180*
Testosterone	5 mg to 100 mg	150

*Estimated beyond-use date (BUD). In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 180 days under refrigeration (2 - 8 °C) or at controlled room temperature (20 - 25 °C) for non-aqueous dosage forms (water activity below 0.6).

The BUDs were determined using an HPLC stability-indicating method. Additional information is available upon request.

APIs not included in these resources can also form elegant, stable compounded preparations that help improve patient comfort and compliance. When no study data is available for a specific API, it is recommended that the pharmacist assign an appropriate expiry date based on internal protocols, risk analyses, or guidelines from accredited pharmacopeias.



Disclaimer

Above are examples of some commonly prescribed formulations across a diverse array of specialties and they are not meant to encourage the use of any formula contained within. Fagron, its owners, officers, agents, affiliates, and employees make no representation or warranty whatsoever with respect to this data. Customer understands and agrees that Fagron, its owners, officers, agents, affiliates, and employees shall not be responsible for any claims, actions, liabilities, losses, expenses, damages, judgment, or costs arising directly or indirectly or related in any way to any actual or alleged injury to any person (including death) resulting from or claimed to result wholly or in part from any formulation that is the same or similar to any Example Formula. No compounded medication is reviewed by the FDA for safety or efficacy. References available upon request.



Fagron BV

Fascinatio Boulevard 350
3065 WB Rotterdam
The Netherlands

T +31 88 33 11 288
F +31 88 33 11 210
www.fagron.com

